Memorial Sloan Kettering Cancer Center

Sloan-kettering Institute for Cancer Research

Samuel Singer

Marta Kovatcheva

Aimee Crago

Andrew C Koff

Gary K Schwartz

William D Tap

Mark A Dickson

Mary Elizabeth Dooley

Andrew Koff

David Liu

Mary Elizabeth Klein

Jin-Hong Chen

Andrew W Koff

The present disclosure relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. Accordingly, in certain non-limiting embodiments, the present disclosure provides for methods, compositions and kits for a companion diagnostic for CDK4 inhibitors, and in particular, for the use of the colocalization of Enigma and CDH18 biomarkers to foci within the cancer for determining whether the cancer can be successfully treated by CDK4 inhibition.

Enigma and CDH18 as companion diagnostics for CDK4 inhibitors

The present invention relates to the use of one or more biomarkers to evaluate the likelihood that a CDK4 inhibitor would produce an anti-cancer effect in a subject. It is based, at least in part, on the discovery that cancer treatment with a CDK4 inhibitor is more effective where treated cancer cells undergo cellular senescence rather than a transient cell cycle arrest, where cellular senescence is associated with decreased MDM2 protein level. Accordingly, in non-limiting embodiments, the present invention provides for methods, compositions, and kits for a companion diagnostic for CDK4 inhibitors, and in particular, to the use of MDM2 expression as a biomarker for the likelihood that a cancer can be successfully treated by CDK4 inhibition.

Companion diagnostic for CDK4 inhibitors

Techniques for corrected nuclear magnetic resonance (NMR) data include applying a presaturation radio frequency (RF) magnetic field different from a fat molecule resonance for a particular time to a target tissue; and applying a first measurement RF magnetic field within a first time after the particular time. Correction nuclear magnetic resonance (NMR) data from the target tissue is determined based on first NMR data received in response to applying the first measurement RF magnetic field. In some embodiments, a second measurement RF magnetic field is also applied in a second time different from both the particular time and the first time. Corrected NMR data is determined by subtracting the correction NMR data from second NMR data received in response to applying the second measurement RF magnetic field. Among other applications, these techniques allow distinguishing either fat or proteins in edemas, or both, from proteins in other tissues.

Corrected nuclear magnetic resonance imaging using magnetization transfer

Growing community of inventors

New York, NY, United States of America

Samuel Singer